glp-1 iih Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review | The Journal of Headache and Pain NeuroOp Guru: Stopping GLP-1 therapy
Description
: FDA- ADA
The boxed warning on Wegovy, Ozempic, Zepbound, and Mounjaro is for medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
As of June 2023, Eli Lilly and Companythe pharmaceutical company behind Mounjarohas published Phase 2 clinical trial results for retatrutide in The New England Journal of Medicine
What do we know about long-term metabolic adaptation
Semaglutides starting dose begins at a modest .25mg, usually administered as a weekly injection, and gradually escalates to a target dose of 2.4mg after roughly 16 weeks
